Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2023

Identificação de duas subpopulações de tofacitinibe com riscos relativos diferentes em relação aos inibidores de TNF: Uma análise do estudo aberto, randomizado e controlado ORAL Survaillance

Ann Rheum Dis. 2023;82(7):901-910 doi: 10.1136/ard-2022-223715

Kristensen LE,

Danese S,

Yndestad A,

Wang C,

Nagy E,

Modesto I,

Rivas J,

Benda B

Findings from a post hoc analysis of ORAL Surveillance can help guide individualised benefit/risk assessment and clinical decision-making on treatment with tofacitinib, based on identification of subpopulations ‘at risk’.

Keywords:

February 2023

Impacto do Enriquecimento do Risco Cardiovascular na Incidência de Eventos Adversos Cardiovasculares Graves no Programa Clínico de Tofacitinibe em Artrite Reumatoide

Ann Rheum Dis. 2023;82(4):575–577 doi: 10.1136/ard-2022-223406

Koch GG,

Wu J,

Wang C,

Kwok K,

Menon S,

Data suggest that an important difference between P123LTE and ORAL Surveillance was the proportion of patients with a history of atherosclerotic CV disease (ASCVD).

Keywords:

October 2022

Risk of MACE with Tofacitinib Versus TNFi in Patients with RA With or Without a History of Atherosclerotic CV: A Post Hoc Analysis from ORAL Surveillance

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-222259

Buch MH,

Koch GG,

Wu J,

Wang C,

Kwok K,

Menon S,

Post hoc analysis from ORAL Surveillance observes higher major adverse cardiovascular events (MACE) risk with tofacitinib vs TNFi in patients with RA and history of atherosclerotic cardiovascular disease (ASCVD).

Keywords:

February 2022

Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis

N Engl J Med 2022;386:316–26. doi: 10.1056/NEJMc2202778

Koch GG,

Menon S,

Sun Y,

Wang C,

Shapiro AB,

Kanik KS,

Connell CA

In this paper, Ytterberg et al. compare incidence of MACE and cancers (excluding NMSC) with tofacitinib 5 mg BID, tofacitinib 10 mg BID and TNFi. They found that risk of MACE and cancer were higher with tofacitinib versus TNFi, and did not meet noninferiority criteria.This prospective head-to-head safety trial compared tofacitinib to TNFi, and was required by the FDA after increases in lipid levels and cancers were observed during tofacitinib drug development. ...

Keywords:

January 2022

Manejo Clínico da Herpes Zoster em Pacientes com Artrite Reumatoide ou Artrite Psoriásica Recebendo Tratamento com Tofacitinib

Rheumatol Ther. 2021. Epub ahead of print. doi: 10.1007/s40744-021-00390-0

Lee EB,

Kwok K,

This post hoc analysis provides the first detailed description of the management and outcomes of HZ events in tofacitinib RA and PsA clinical studies.While prior studies have characterised the increased HZ risk with JAKinibs, the clinical management of these events has not been detailed.To this end, Winthrop, et al. analysed data from 21 RA and 3 PsA clinical studies to evaluate how HZ events and their sequelae were clinically managed during the RA and PsA tofacitinib clinical development progra...

Keywords:

Taxas de incidência de doença intersticial pulmonar em pacientes com artrite reumatoide tratados com tofacitinib

J Clin Rheumatol. 2021;27(8):e482–e490

Park JK,

Kwok K,

Wang L,

Ponce de Leon D

This post hoc analysis of pooled data from 21 clinical trials in the tofacitinib clinical trial programme highlights the importance of identifying known risk factors of RA-interstitial lung disease (ILD) in clinical practice.Citera, et al. investigated incidence rates of ILD – an extra-articular manifestation of RA – in patients with RA, receiving tofacitinib 5 or 10 mg BID and sort to identify potential risk factors for ILD in these patients....

Keywords:

March 2021

Estudo de Segurança Comparativa Pós-Aprovação de Tofacitinib e Fármacos Biológicos Antirreumáticos Modificadores de Doença: Resultados de 5 anos de um Registro de Artrite Reumatoide Sediado nos Estados Unidos

ACR Open Rheumatol. 2021 Feb 11.

Geier J,

Barr CJ,

Analysis from the US Corrona RA registry has provided the longest-term real-world safety data for a JAK inhibitor to date. The analysis showed that the cohorts had similar adverse events, except for higher herpes zoster rates for tofacitinib initiators vs bDMARDs.Kremer JM, et al. analysed adult patients with RA newly initiating tofacitinib, or a bDMARD, to compare incidence rates of MACE, SIEs, HZ, malignancies and death. VTE data were also collected prospectively and assessed descriptively thr...

Keywords:

September 2020

https://drive.google.com/file/d/1kYemQVjGOIePWjcDZX8FCKHAwLmIzByZ/view?usp=sharing

Journal of Clinical Rheumatology, Aug 2020 doi: 10.1097/RHU.0000000000001552.

Kwok K,

This study highlights the importance of accounting for known risk factors of RA-ILD in clinical practice. Interstitial lung disease (ILD) is an extra-articular manifestation of RA. The post-hoc investigated incidence rates of ILD in patients with RA, receiving tofacitinib 5 or 10 mg twice daily, and identified potential risk factors for ILD. This post-hoc analysis comprised a pooled analysis of patients receiving tofacitinib 5 or 10 mg twice daily or placebo from 21 Phase 1-4, and 2 long-term ex...